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ABSTRACT- The consistently demonstrable antitumor effect of
Corynebacterium parvum and BCG against a 7,12-dimethyl-
benz[aJanthracene-lnduced rat flbrosarcoma, growlng either as a
localized subcutaneous tumor or in ascites form, was abrogated
by treatment of rats with antlmacrophage agents such as slllca or
carrageenan.-J Natl Cancer Inst 59: 1751-1753, 1977.
Numerous infectious agents, such as BCG (1, 2),
Corynebacterium (3), Toxoplasma (4), or nematode para-
sites (5), as well as irritants such as endotoxin (6),
peptone (7), glucan, or synthetic pyrans (8, 9), which
can stimulate the mononuclear phagocyte system and
potentiate the immune response against various anti-
gens, also have considerable antitumor activity in vivo.
Depending on the route and timing of administration
of such agents, macrophages acquire the capacity to kill
neoplastic cells in vitro with considerable selectivity (8,
10-13). Other observations imply an inverse relationship
between the macrophage content of tumors and tumor
regression (14) or metastasis (15). However, direct evi-
dence that macrophages are involved in tumor resist-
ance continues to be elusive.
It has recently been shown that treatment of the host
with agents that diminish the functional capacities of
macrophages in vitro markedly enhanced tumor growth
in vivo (16). The present work demonstrates that the
widely recognized antitumor activity of Corynebacterium
parvum and BCG is entirely annulled by treatment with
these same antimacrophage agents.
MATERIALS AND METHODS
Animal5.-Inbred female DA rats, weighing 150-200 g,
were used and maintained under conventional condi-
tions.
Tumors.-Tumors were induced with DMBA and pas-
saged in vivo as described in (7). One of these tumors,
DMBA 12, which had progressively lost its immunogen-
icity during in vivo passages, acquired the capacity to
grow, at least for a restricted number of passages, in
ascites form. In these experiments, ascites tumor cells
were injected either sc or ip into the DA rats.
BCG.-Living organisms of the Pasteur strain of BCG
were obtained from the mycobacterial collection of the
Trudeau Institute, Saranac Lake, New York (TMC
#1011), stored in glass vials, and kept at -850 C until
used in order to inhibit tumor growth (table 1).
C. parvum.-e. parvum organisms (strain 2683, Insti-
tut Pasteur) were cultured as described in (17). Heat-
killed organisms were harvested by means of centrifu-
gation, washed three times in 0.15 ml saline, and freeze
dried. On the day indicated for each experiment, 3 mg
of C. parvum was injected either sc or ip.
Antimacrophage agents.-Silica particles (Dörentrup
quartz, # 12; average diameter, 5 f.L) were suspended in
PBS and injected as indicated for each experiment.
Carrageenan (Sea Kern 21; Marine Colloids, Inc.,
Springfield, N.J.) was dissolved in PBS by being heated
to 1000 C for 15 minutes in a water bath; rats were
given 5 mg in PBS either iv or ip as indicated for each
experiment.
RESULTS
The effects of C. parvum and/or BCG and of silica
particles and/or carrageenan on the growth of local
subcutaneous tumors and of ascites tumors were as-
sessed separately.
Effects of C. parvum and/or BCG and of Silica
Particles and/or Carrageenan on a Progressively
Growing, Local Subcutaneous Tumor
The sc inoculation of 103-104 DMBA 12 tumor cells
led to rapidly growing, local subcutaneous tumors; in
the controls, tumors reached a considerable weight
within 3 weeks (table 1). Pretreatment of rats with C.
partnun or BCG distinctly diminished tumor growth.
On the contrary, treatment on the day of tumor cell
inoculation with carrageenan and particularly with silica
particles significantly enhanced local tumor growth. In
animals pretreated with C. partrum or BCG, the antitu-
mor effect was fully reversed by silica or carrageenan
ABBREVIATIONS USED: DMBA = 7,12-dimethylbenz[a]anthracene; PBS
= phosphate-buffered saline.
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TABLE l.-Inhibition of the growth ofsubcutaneous tumors by BeG
andlor C. parvum and its reversal by silica andlor carrageenan
Tumor treatment" Tumor weight, gb
to similar increase in antitumor resistance, which was
likewise abrogated by ip treatment of rats with the
antimacrophage agents (not shown).
administered on day O. Results such as those in table
have been obtained in several other experiments.
Results of a typical experiment are represented in
text-figure 1. In controls, ip inoculation of 103 DMBA-
Antimacrophage agents, such as silica and carra-
geenan, have been shown to promote the growth of a
syngeneic tumor of low immunogenicity (16); this find-
ing indicates that in tumor-bearing rats these agents
diminished innate resistance to tumors. The present
work shows that in accordance with numerous earlier
observations, microbial agents with adjuvant activity,
such as C. partnun and BCG, consistently exert antitu-
mor activity, especially when given prior to tumor
implantation. The antitumor effects of these agents
were similarly manifested in tumors growing subcuta-
neously and in the ascites form. Administration of silica
or carrageenan on the same day as the tumor cell
inoculum was injected cancelled out the beneficial ef-
fects of C. partrum or BCG. Antitumor resistance of rats
pretreated with adjuvants and then given silica or car-
rageenan was frequently even lower than that in un-
treated controls, i.e., was similar to that in rats given
silica or carrageenan alone. Since the present work was
completed, similar observations have been reported by
Hopper et al. (18).
In recent years, varied indirect evidence suggested a
crucial role for macrophages in surveillance against
neoplastic transformation [reviewed and discussed in
(19-:-21)]. Diverse observations indicate that antitumor
activity of various biologie and synthetic immunopoten-
tiators, such as BCG, C. parvum, glucans, and pyrans, is
mediated predominantly by mononuclear phagocytes.
In in vitro situations, silica and carrageenan damage
macrophages selectively; however, there are no analo-
gous data to show that the in vitro effects of these
agents also apply in vivo. After treatment with silica
and/or carrageenan, abrief period of clearly dimin-
ished macrophage function can be discerned (16). Con-
ceivably, this period , short as it is, could contribute to
tumor implantation and initiation of progressive tumor
growth. However, it is equally possible that tumor
growth is enhanced by agents released from damaged
macrophages (16). The present findings provide fur-
ther evidence for the concept of an effective role for
mononuclear phagocytes in natural tumor resistance,
but in view of the complexity of the in vivo situation,
they cannot be taken as a final proof for such a function
of macrophages.
DISCUSSION
21.8±4.4
26.3±8.3d
21.8±3.5d
16.8±2.9
7.4±3.7c
7.6±2.2c
24.4±4.7C
26.8±4.9c
24.6±4.9c
Controls
108 BCG sc on day -5
3 mg e.parvum sc on day -7
108 BCG sc on day -5; 5 mg carrageenan iv on
day 0
108 BCG sc on day -5; 10 mg silica iv on day 0
3 mg e. parvum sc on day -7; 10 mg silica iv on
day 0
3 mg e. parvum sc on day -7; 5 mg carrageenan
iv on day 0
10 mg silica iv on day 0
5 mg carrageenan iv on day 0
Effects of C. parvum and/or BCG and of Silica
Particles and/or Carrageenan on Growth of Ascites
Tumor
a On day 0, 104 tumor cells were injected sc; the rats were killed
and tumor weights were assessed on day 16.
b Each value represents the mean of 12 rats ±SD.
c Values are significantly different (P<0.001) from those for the
controls, as determined by Student's t-test.
d Values are significantly different (P<0.005) from those for the
controls, as determined by Student's t-test.
2S 30 3S 38
Days after ip inocu1ation of 10 3 DMBA-
induced syngeneic ascites tumor ce11s
TEXT-FIGURE l.-Inhibition of ascites tumor growth by pretreatment
with C. parvum and abrogation of this effect by silica and/or
carrageenan. 0, controls; 6., 3 mg C. paroum was injected ip on day
-10; 0, 10 mg silica was injected ip on day 0; ., 5 mg carrageenan
was injected ip on day 0; ., C. parvum+silica; ..., C. parvum+carra-
geenan.
induced syngeneic ascites tumor cells led to progressive
tumor growth; within approximately 3 weeks, all rats
died of tumors. In rats pretreated ip with 3 mg C.
partnun on day -10, the survival time was prolonged by
1 to 3 weeks. This antitumor effect of C. partrum was
consistently abrogated by silica and/or carrageenan ad-
ministered on the day of tumor cell inoculation. Pre-
treatment with 108 BCG cells injected ip on day -7 led
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